technetium Tc 99m succimer

Action and Spectrum

Actions and Spectrum: 

technetium Tc 99m succimer is a radiopharmaceutical used in nuclear medicine imaging. Here’s some information about its action and spectrum: 

Action: technetium Tc 99m succimer is primarily used for renal (kidney) imaging. It works by being taken up by the kidneys and excreted in the urine, allowing imaging of the renal system. This radiopharmaceutical is particularly useful in evaluating the function and structure of the kidneys and detecting any abnormalities or diseases affecting the renal system. 

Spectrum: The term “spectrum” typically refers to the energy spectrum of the gamma rays emitted by a radiopharmaceutical. technetium Tc 99m succimer emits gamma rays with a characteristic energy of 140 keV (kilo-electron volts). This energy is ideal for detection by gamma cameras, which are commonly used in nuclear medicine imaging. 

The gamma rays emitted by technetium Tc 99m succimer can be detected by a gamma camera, which captures the radiopharmaceutical distribution in the patient’s body. This allows healthcare professionals to obtain detailed images of the kidneys and surrounding structures, helping diagnose and manage various renal conditions. 

Drug Interaction

Adverse Reaction

Frequency not defined 

Rash 

Erythema 

Pruritus 

Syncope 

Hypersensitivity  

Nausea 

Urticaria 

Fever 

Black Box Warning

Black Box Warning: 

None 

Contraindication / Caution

Contraindication/Caution: 

Contraindication 

technetium Tc 99m succimer, known as dimercaptosuccinic acid (DMSA), is generally well tolerated and has few absolute contraindications. However, there are a few precautions and relative contraindications to be aware of. Here are some considerations: 

• Hypersensitivity: technetium Tc 99m succimer should not be administered to individuals with known hypersensitivity or allergy to DMSA or its components. 
• Pregnancy and breastfeeding: As with any radiopharmaceutical, using technetium Tc 99m succimer during pregnancy or breastfeeding should be carefully considered. The potential risks and benefits should be assessed, and alternative imaging modalities may be considered. 
• Renal impairment: technetium Tc 99m succimer is primarily used for renal imaging. However, if a patient has severe renal impairment or end-stage renal disease, the administration and clearance of the radiopharmaceutical may be altered. In such cases, the decision to use technetium Tc 99m succimer should be made cautiously, and the dosage and imaging protocol may need to be adjusted. 
• Allergic reactions: While rare, allergic reactions to technetium Tc 99m succimer or other radiopharmaceuticals can occur. Suppose a patient has a history of allergic reactions to similar agents. In that case, caution should be exercised, and appropriate measures should be taken to manage any potential allergic reactions during the imaging procedure. 

It’s important to note that contraindications may vary based on specific patient factors, imaging protocols, and regional guidelines. Therefore, consulting with a healthcare professional or nuclear medicine specialist who can evaluate individual circumstances and provide accurate and up-to-date information regarding using technetium Tc 99m succimer is always advisable. 

Caution 

While there may not be specific contraindications for technetium Tc 99m succimer, several cautions should be considered when using this radiopharmaceutical. Here are some general cautions: 

• Radiation exposure: technetium Tc 99m succimer is a radiopharmaceutical that emits ionizing radiation. Although the doses used in diagnostic imaging are generally considered safe, precautions should be taken to minimize radiation exposure, especially in vulnerable populations such as pregnant women, children, and individuals who may be more sensitive to radiation. 
• Renal function: technetium Tc 99m succimer is primarily used for renal imaging. However, caution should be exercised if a patient has impaired renal function or a history of renal disease. The imaging protocol and dosage may need to be adjusted accordingly. 
• Drug interactions: technetium Tc 99m succimer may interact with other medications. It’s essential to inform the healthcare provider about all the medications, supplements, and also herbal products you are taking to ensure that no potential interactions could affect the imaging results or your safety. 
• Allergic reactions: While rare, allergic reactions to technetium Tc 99m succimer or other radiopharmaceuticals can occur. Patients with a history of allergies or hypersensitivity should be closely monitored during the imaging procedure, and also measures should be in place to manage any potential allergic reactions. 
• Pediatric use: technetium Tc 99m succimer can be used in pediatric patients, but appropriate considerations should be made for their age, weight, and renal function. Pediatric imaging protocols and radiation doses may differ from those used in adults. 

It’s important to discuss any specific concerns or conditions with your healthcare provider or nuclear medicine specialist before undergoing any imaging procedure with technetium Tc 99m succimer. They can provide personalized information and guidance based on your circumstances. 

Pregnancy / Lactation

Pregnancy consideration:  

US FDA pregnancy category: Not assigned 

Lactation:   

Excreted into human milk: Yes 

Pregnancy category: 

• Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester. 
• Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women. 
• Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.    
• Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.    
• Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.    
• Category N: There is no data available for the drug under this category 

Pharmacology

Pharmacology: 

technetium Tc 99m succimer (dimercaptosuccinic acid, DMSA) is a radiopharmaceutical used in nuclear medicine imaging. Its pharmacology involves the following aspects: 

• Radiopharmaceutical Properties: technetium Tc 99m succimer is a complex compound containing a radioactive isotope called technetium-99m (Tc 99m). This isotope emits gamma rays, which gamma cameras can detect during imaging procedures. 
• Selective Renal Uptake: The renal system primarily takes up technetium Tc 99m succimer. After intravenous administration, it is rapidly cleared from the bloodstream and accumulates in the cortical tissue of the kidneys. The precise mechanism of selective renal uptake is not fully understood, but it is typically believed to involve passive diffusion and binding to specific receptors in the renal tissue. 
• Renal Excretion: Once taken up by the kidneys, technetium Tc 99m succimer undergoes minimal metabolism. It is excreted predominantly through glomerular filtration into the urine. This renal excretion allows for the visualization of the renal system during imaging. 
• Gamma Ray Emission: technetium Tc 99m succimer emits gamma rays with an energy of 140 kiloelectron volts (keV). These gamma rays can penetrate the body tissues and are detected by gamma cameras, which create images that reflect the distribution and function of the radiopharmaceutical in the kidneys. 
• Radiation Safety: technetium Tc 99m succimer is administered in diagnostic doses that are generally considered safe. The radiation exposure to the patient is minimized, and the radiopharmaceutical’s half-life (approximately 6 hours for Tc 99m) ensures that most of the radiation is cleared from the body within a short period. 

Pharmacodynamics: 

Mechanism of action: technetium Tc 99m succimer (dimercaptosuccinic acid, DMSA) is not a pharmacologically active agent. Instead, it is a radiopharmaceutical used for imaging purposes in nuclear medicine, particularly for renal (kidney) imaging. The mechanism of action of technetium Tc 99m succimer is based on its selective uptake and distribution in the kidneys. 

Pharmacokinetics: 

Absorption 

technetium Tc 99m succimer is administered intravenously, typically as a radiolabeled solution. After injection, it quickly enters the bloodstream and distributes throughout the body. 

Distribution 

technetium Tc 99m succimer shows selective distribution to the renal system. The kidneys take it up, and it accumulates in the cortical tissue. The exact mechanism of selective renal uptake is not fully understood, but it is typically believed to involve passive diffusion and specific binding to renal receptors. 

Metabolism 

technetium Tc 99m succimer undergoes minimal metabolism in the body. It remains essentially unchanged from its administered form. The compound is stable and does not undergo significant chemical changes during its residence in the body. 

Elimination and Excretion 

technetium Tc 99m succimer is primarily excreted through the kidneys. After renal uptake, it is filtered by the glomeruli and excreted into the urine. The excretion of technetium Tc 99m succimer occurs relatively quickly, allowing for efficient imaging of the renal system. 

Adminstartion

Administration: 

Intravenous administration 

technetium Tc 99m succimer (dimercaptosuccinic acid, DMSA) is typically administered intravenously for renal imaging. The exact administration protocol may vary depending on the specific imaging procedure and the healthcare facility’s guidelines. Here is a general overview of the administration process: 

• Preparation: technetium Tc 99m succimer is prepared by a trained nuclear medicine technologist or pharmacist. It is usually supplied as a kit containing the necessary components for radiolabeling. 
• Radiolabeling: The kit is reconstituted with a sodium pertechnetate Tc 99m solution, a radioactive isotope of technetium. Radiolabeling is performed in a shielded environment following appropriate radiation safety procedures. 
• Patient preparation: Before administering technetium Tc 99m succimer, the patient is typically asked to drink plenty of fluids to ensure adequate hydration. This helps optimize the excretion of the radiopharmaceutical through the renal system. 
• Injection: technetium Tc 99m succimer is injected into a vein, usually in the arm. The dosage and injection technique may vary depending on the specific imaging protocol and the patient’s age and weight. 
• Imaging acquisition: After the injection, the patient is usually asked to lie still on a table or imaging bed. A gamma camera is positioned over the area of interest, typically focusing on the kidneys. The gamma camera locates the gamma rays emitted by the radiopharmaceutical and creates images of the renal system. 

The exact imaging protocol, including the timing and duration of image acquisition, will depend on the specific purpose of the examination and the healthcare facility’s guidelines. 

It’s important to note that the administrative procedure should be performed by trained healthcare professionals, such as nuclear medicine technologists or radiologists, following appropriate radiation safety protocols. 

Patient Information Leaflet

Patient information leaflet 

Generic Name: technetium Tc 99m succimer 

Pronounced: [ tek-NEE-shee-um-Tc-99m-SUX-i-mer ] 

Why do we use technetium Tc 99m succimer? 

technetium Tc 99m succimer (dimercaptosuccinic acid, DMSA) is primarily used for renal imaging in nuclear medicine. It is commonly used to evaluate the kidneys’ structure and function and detect abnormalities or diseases affecting the renal system. Here are some specific uses of technetium Tc 99m succimer: 

• Renal scintigraphy: technetium Tc 99m succimer is widely used in renal scintigraphy, a non-invasive imaging technique to assess the kidneys. It provides detailed information about the kidneys’ size, shape, position, and function. Renal scintigraphy with technetium Tc, 99m succimer, helps diagnose and manage various conditions, such as renal parenchymal disorders, renal artery stenosis, congenital abnormalities, and urinary tract obstruction. 
• Differential renal function: technetium Tc 99m succimer can determine the individual kidney function and evaluate the split function in cases of concerns about kidney function asymmetry or potential kidney diseases. It helps assess the functional contribution of each kidney, which is valuable in planning surgical interventions or monitoring disease progression. 
• Renal cortical imaging: technetium Tc 99m succimer helps assess the cortical distribution and integrity of the renal tissue. It can help identify areas of decreased or absent renal cortical uptake, which may indicate scarred or non-functioning areas within the kidneys. 
• Follow-up evaluation: technetium Tc 99m succimer imaging can be employed to monitor the progression of renal diseases, evaluate treatment responses, and assess the effectiveness of interventions, such as renal artery revascularization or surgical repair of urinary tract obstructions. 

It’s important to note that the specific uses of technetium Tc 99m succimer may vary depending on individual patient factors, clinical indications, and the healthcare provider’s preferences. The administration and interpretation of imaging studies should be performed by qualified healthcare professionals experienced in nuclear medicine.